• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by 60 Degrees Pharmaceuticals Inc.

    11/13/25 3:49:34 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SXTP alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    60 DEGREES PHARMACEUTICALS, INC.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    83006G401

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    83006G401


    1Names of Reporting Persons

    Ayrton Capital LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    177,427.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    177,427.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    177,427.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.14 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    83006G401


    1Names of Reporting Persons

    Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    177,427.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    177,427.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    177,427.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.14 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    83006G401


    1Names of Reporting Persons

    Waqas Khatri
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    177,427.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    177,427.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    177,427.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.14 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    60 DEGREES PHARMACEUTICALS, INC.
    (b)Address of issuer's principal executive offices:

    1025 Connecticut Avenue NW Suite 1000 Washington, D.C X1 20036
    Item 2. 
    (a)Name of person filing:

    (i) Ayrton Capital LLC; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B; and (iii) Waqas Khatri
    (b)Address or principal business office or, if none, residence:

    (i) Ayrton Capital LLC, 55 Post Rd West, 2nd Floor Westport, CT 06880; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, Suite #7 Grand Pavilion Commercial Centre, 802 West Bay Road, Grand Cayman, P.O. Box 10250, Cayman Islands; and (iii) Waqas Khatri 55 Post Rd West, 2nd Floor Westport, CT 06880
    (c)Citizenship:

    (i) Ayrton Capital LLC: United States; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: Cayman Islands; and (iii) Waqas Khatri: United States
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    83006G401
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Ayrton Capital LLC: 177,427; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B:177,427; and (iii) Waqas Khatri: 177,427. Represents 177,427 shares of Common Stock issuable on the exercise of certain warrants (the "Warrants") held by the Reporting Persons. The issuable shares of Common Stock related to the exercise of the Warrants are subject to a 9.99% beneficial ownership blocker. The shares reported herein represent Common Stock of 60 DEGREES PHARMACEUTICALS, INC. (the "Issuer") held by Alto Opportunity Master Fund, SPC- Segregated Master Portfolio B, a Cayman Islands exempted company (the "Fund"). The Fund is a private investment vehicle for which Ayrton Capital LLC, a Delaware limited liability company (the "Investment Manager"), serves as the investment manager. Waqas Khatri serves as the managing member of the Investment Manager (all of the foregoing, collectively, the "Reporting Persons").
    (b)Percent of class:

    The percentages below are based on (i) 4,104,469 shares of Common Stock of the Issuer that were outstanding as of September 3, 2025; and (ii) 177,427 shares of Common Stock issuable on the exercise of the Warrants held by the Reporting Persons. The amount of shares outstanding was based upon a statement in the Issuer's 424B5 Prospectus filed on September 5, 2025. For the sake of clarity, the holdings of the Reporting Persons reported herein are as of September 30, 2025. (i) Ayrton Capital LLC: 4.14%; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 4.14%; and (iii) Waqas Khatri: 4.14%.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (i) Ayrton Capital LLC: 177,427; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 177,427; and (iii) Waqas Khatri: 177,427

     (ii) Shared power to vote or to direct the vote:

    (i) Ayrton Capital LLC: 0; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 0; and (iii) Waqas Khatri: 0

     (iii) Sole power to dispose or to direct the disposition of:

    (i) Ayrton Capital LLC: 177,427; Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 177,427; Waqas Khatri:177,427

     (iv) Shared power to dispose or to direct the disposition of:

    (i) Ayrton Capital LLC: 0; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 0; (iii) Waqas Khatri: 0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Ayrton Capital LLC
     
    Signature:/s/ Waqas Khatri
    Name/Title:Waqas Khatri / Managing Member
    Date:11/13/2025
     
    Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B
     
    Signature:/s/ Waqas Khatri
    Name/Title:Waqas Khatri / Director
    Date:11/13/2025
     
    Waqas Khatri
     
    Signature:/s/ Waqas Khatri
    Name/Title:Waqas Khatri
    Date:11/13/2025
    Get the next $SXTP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SXTP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SXTP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Dow Geoffrey S was granted 7,201 shares, increasing direct ownership by 28% to 33,372 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    9/15/25 4:38:01 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Operating Officer Landon Kristen

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    8/14/25 9:24:37 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Landon Kristen was granted 4,540 shares (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    8/14/25 9:23:53 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SXTP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine

    90-day trial will measure change in general fatigue in patients with chronic babesiosis following tafenoquine treatmentStudy will run approximately 12 months and enroll up to 100 patientsInternal estimates of the unmet medical need are between 4,400 and 190,000 cases annually, with no existing FDA-approved treatment for babesiosis WASHINGTON, Nov. 21, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the central study site for the Company's B-FREE Chronic Babesiosis Study, the Cohen Center for Recovery from Comple

    11/21/25 8:01:00 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

    Q3 2025 net product revenue increased 223% year-over-year to $438 thousandGross profit/(loss) decreased from $24 thousand to $(100) thousand WASHINGTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, reported today its financial results for the third fiscal quarter of the 2025 year, ended September 30, 2025. Financial Highlights for the Quarter Ended September 30, 2025: ARAKODA® pharmacy deliveries increased by 14% from 1,319 boxes (Q3 2024) to 1,505 boxes (Q3 2025).The Company posted a gross loss of approximately $100 thousand in the th

    11/13/25 1:51:00 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

    Breakthrough Therapy Designation request has been submitted to FDACompany to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA)Results obtained using highest sensitivity test available; licensed by FDA for blood donation screeningRemaining enrolled patients will complete the study between January and October 2026Study intended to confirm the high cure rate for tafenoquine in immunosuppressed patients with relapsing babesiosis, as reported by Yale in a 2024 publication WASHINGTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical com

    10/15/25 7:14:00 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SXTP
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by 60 Degrees Pharmaceuticals Inc.

    SCHEDULE 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

    11/13/25 3:49:34 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by 60 Degrees Pharmaceuticals Inc.

    10-Q - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    11/13/25 1:31:01 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by 60 Degrees Pharmaceuticals Inc.

    SCHEDULE 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

    11/7/25 5:30:52 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SXTP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Xu Cheryl bought $14,410 worth of shares (5,000 units at $2.88), increasing direct ownership by 46% to 15,816 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    6/5/25 8:53:09 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Xu Cheryl bought $21,400 worth of shares (13,000 units at $1.65), increasing direct ownership by 32% to 54,078 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/18/24 8:35:59 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Dow Geoffrey S bought $89,755 worth of shares (73,951 units at $1.21), increasing direct ownership by 358% to 94,580 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/9/24 5:07:49 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SXTP
    Financials

    Live finance-specific insights

    View All

    VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / December 2, 2024 / RedChip Companies aired interviews with VSee Health, Inc. (NASDAQ:VSEE) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV on November 30. Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:VSEE: https://www.redchip.com/assets/access/vsee_accessSXTP: https://www.redchip.com/assets/access/sxtp_accessIn an exclusive interview, Imo Aisiku, M.D., co-CEO and Chairman of VSee Health, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share insight into how VSee Health's differentiated so

    12/2/24 4:05:00 PM ET
    $SXTP
    $VSEE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services

    60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Can-Fite BioPharma Ltd. (NYSE:CANF)(TASE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:SXTP: https://www.redchip.com/assets/access/sxtp_accessCANF: https://www.redchip.com/assets/access/canf_accessIn an exclusive interview, Geoffrey Dow, CEO and President of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on

    11/22/24 9:00:00 AM ET
    $CANF
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report® on Bloomberg TV

    MELBOURNE, Australia, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to advise that RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and 60 Degrees Pharmaceuticals (60P) (NASDAQ:SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: •  Genetic Technologies (NASDAQ:GENE): https://www.redchip.com/

    9/1/23 10:00:00 AM ET
    $GENE
    $SXTP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $SXTP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by 60 Degrees Pharmaceuticals Inc.

    SC 13G - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

    11/14/24 3:37:18 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by 60 Degrees Pharmaceuticals Inc.

    SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

    11/13/24 4:01:15 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by 60 Degrees Pharmaceuticals Inc. (Amendment)

    SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

    5/7/24 7:19:08 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care